Health Technology · Pharmaceuticals: Major · NSE: PANACEABIO · data 2026-10-09

Panacea Biotec Limited

Health check: Weak (1/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹345.25

Market cap

₹2,106 cr

P/E

—

P/B

—

ROE

-0.6%

ROCE

-6.3%

Debt / equity

0.03

Dividend yield

0.00%

1-year return

-20.9%

52-week high

₹647

52-week low

₹292.4

Operating margin

-4.5%

Growth

Revenue (last 12 months)	₹673 cr
Net profit (last 12 months)	₹-7 cr
Sales growth, 3 years (yearly)	10.1%
Profit growth, 3 years (yearly)	—

Similar companies

Sai Parenterals Limited (SAIPARENT) · Sakar Healthcare Ltd (SAKAR) · Indoco Remedies Limited (INDOCO) · Beta Drugs Ltd. (BETA) · Windlas Biotech Ltd. (WINDLAS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open PANACEABIO in NSE Scanner →